💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Buprenorphine

CHEMBL511142 Phase 4 Approuvé Small molecule
Half-Life
24-42 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
467.6 g/mol
LogP
5.0
Phase
4

A partial opioid agonist used both for the treatment of opioid use disorder and for moderate-to-severe pain management. At lower doses, it suppresses opioid cravings and withdrawal symptoms while reducing the euphoric effects of other opioids. Its ceiling effect on respiratory depression makes it safer in overdose compared to full opioid agonists.

Masse moléculaire

467,6430 g/mol

LogP

5,00

TPSA

62,20 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Psychiatry Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Schizophrenia Generalized Anxiety Disorder Insomnia Obesity Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Prostate Cancer Colorectal Cancer

Classes de médicaments

N — N - Nervous System

Mécanisme d'action

Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.

Pharmacokinetics (PK)

Half-Life 24-42 hours

Pharmacodynamics (PD)

Mécanisme

Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5

                

                

                
                

                    
InChI

                    
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29+/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C29H41NO4

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
Liaisons Rotatives

                        
5

                    

                    
                    
                    

                        
Atomes Lourds

                        
34

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
A partial opioid agonist used both for the treatment of opioid use disorder and for moderate-to-severe pain management. At lower doses, it suppresses opioid cravings and withdrawal symptoms while reducing the euphoric effects of other opioids. Its ceiling effect on respiratory depression makes it safer in overdose compared to full opioid agonists.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Buprenorphine: Half-life: 24-42 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Buprenorphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL511142.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 644073.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.